Cardiovascular Risk in Survivors of Cancer

  • Henry Chen Zheng
  • Laura Onderko
  • Sanjeev A. Francis
Cardio-Oncology (SA Francis, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Cardio-Oncology


Purpose of Review

Survivors of childhood and adult cancers face increased risk of cardiovascular disease. We review the current evidence base and guidelines for this rapidly growing population.

Recent Findings

Research continues to show that cardiovascular disease is an important cause of morbidity and mortality in cancer survivors. Cardiotoxicity related to chemotherapy and radiotherapy accounts for part of this increased risk. There is emerging evidence that cancer and cardiovascular disease share a similar biology and risk factors.


At present, there are several guidelines and consensus recommendations for the management of cardiovascular risk in cancer survivors. The evidence base is accumulating though additional research is necessary to demonstrate improved outcomes and comparative effectiveness.


Survivorship Cardiotoxicity Chemotherapy-associated cardiomyopathy Screening guidelines 


Compliance with Ethical Standards

Conflict of Interest

Henry Chen Zheng, Laura Onderko, and Sanjeev A. Francis declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. 1.
  2. 2.
    Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220–41. doi: 10.3322/caac.21149.CrossRefPubMedGoogle Scholar
  3. 3.
  4. 4.
  5. 5.
    •• Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. Longo DL, ed. N Engl J Med. 2016;375(15):1457–1467. doi: 10.1056/NEJMra1100265. This review provides a comprehensive overview of cardiovascular toxicity due to novel targeted cancer therapies.
  6. 6.
    Yeh ETH, Bickford CL. Cardiovascular complications of cancer therapy. JACC JAC. 2009;53(24):2231–47. doi: 10.1016/j.jacc.2009.02.050.CrossRefGoogle Scholar
  7. 7.
    Hahn VS, Lenihan DJ, Ky B. Cancer therapy–induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies. J Am Heart Assoc. 2014;3(2):–e000665. doi: 10.1161/JAHA.113.000665.
  8. 8.
    Steinherz LJ, Steinherz PG, Tan CTC, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991;266(12):1672–7. doi: 10.1001/jama.1991.03470120074036.CrossRefPubMedGoogle Scholar
  9. 9.
    Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;324(12):808–15. doi: 10.1056/NEJM199103213241205.CrossRefPubMedGoogle Scholar
  10. 10.
    Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the childhood cancer survivor study cohort. BMJ. 2009;339(dec08 1):b4606. doi: 10.1136/bmj.b4606.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015; doi: 10.1161/CIRCULATIONAHA.114.013777.
  12. 12.
    Galper SL, Yu JB, Mauch PM, et al. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood. 2011;117(2):412–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Heidenreich PA, Hancock SL, Lee BK, Mariscal CS, Schnittger I. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol. 2003;42(4):743–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA. 2003;290(21):2831–7.CrossRefPubMedGoogle Scholar
  15. 15.
    •• Lancellotti P, Nkomo VT, Badano LP, et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J Am Soc Echocardiogr. 2013;26(9):1013–32. doi: 10.1016/j.echo.2013.07.005. This expert consensus document provides a nice review of radiation-associated heart disease as well as practical guidelines for the practicing clinician. CrossRefPubMedGoogle Scholar
  16. 16.
    Groarke JD, Nguyen PL, Nohria A, Ferrari R, Cheng S, Moslehi J. Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease. Eur Heart J. 2014;35(10):612–23. doi: 10.1093/eurheartj/eht114.CrossRefPubMedGoogle Scholar
  17. 17.
    Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987–98. doi: 10.1056/NEJMoa1209825.CrossRefPubMedGoogle Scholar
  18. 18.
    Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365:1273–83.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–84.CrossRefPubMedGoogle Scholar
  20. 20.
    Suter TM, Procter M, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol. 2007;25:3859–65.CrossRefPubMedGoogle Scholar
  21. 21.
    Chen J, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol. 2012;60(24):2504–12. doi: 10.1016/j.jacc.2012.07.068.CrossRefPubMedGoogle Scholar
  22. 22.
    Lenihan DJ, Oliva S, Chow EJ, Cardinale D. Cardiac toxicity in cancer survivors. Cancer. 2013;119(Suppl 11):2131–42.CrossRefPubMedGoogle Scholar
  23. 23.
    Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Annals of oncology : official journal of the European Society for Medical Oncology. 2012;23(Suppl 7):vii155–66.CrossRefGoogle Scholar
  24. 24.
    Hunt SA, Abraham WT, Chin MH, et al. Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119(14):e391–479.CrossRefPubMedGoogle Scholar
  25. 25.
    Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55(3):213–20.CrossRefPubMedGoogle Scholar
  26. 26.
    Groarke JD, Nohria A. Anthracycline cardiotoxicity: a new paradigm for an old classic. Circulation. 2015;131(22):1946–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Silber JH, Cnaan A, Clark BJ, et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004;22(5):820–8.CrossRefGoogle Scholar
  28. 28.
    National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Survivorship Guidelines. Version 2. 2016.Google Scholar
  29. 29.
    •• Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography. 2014;27(9):911–39. This expert consensus provides a nice review of chemotherapy-associated heart disease and provides practical guidelines for the practicing clinician particularly in regard to the role of cardiac imaging in the screening, diagnosis, and follow-up of patients with cardiotoxicity. CrossRefGoogle Scholar
  30. 30.
    Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. Circulation. 2016;133(11):1104–14. doi: 10.1161/CIRCULATIONAHA.115.020406.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    van der Pal HJ, van Dalen EC, van Delden E, et al. High risk of symptomatic cardiac events in childhood cancer survivors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(13):1429–37.CrossRefGoogle Scholar
  32. 32.
    Franco VI, Lipshultz SE. Cardiac complications in childhood cancer survivors treated with anthracyclines. Cardiol Young. 2015;25(Suppl 2):107–16.CrossRefPubMedGoogle Scholar
  33. 33.
    Children’s Oncology Grop. Long-term follow-up guidelines for survivors of childhood, adolescent and young adult cancers Version 4.0. 2013.Google Scholar
  34. 34.
    Sieswerda E, Postma A, van Dalen EC, et al. The Dutch Childhood Oncology Group guideline for follow-up of asymptomatic cardiac dysfunction in childhood cancer survivors. Annals of oncology : official journal of the European Society for Medical Oncology. 2012;23(8):2191–8.CrossRefGoogle Scholar
  35. 35.
    Wallace WH, Thompson L, Anderson RA, Guideline Development G. Long term follow-up of survivors of childhood cancer: summary of updated SIGN guidance. BMJ. 2013;346:f1190.CrossRefPubMedGoogle Scholar
  36. 36.
    United Kingdon Children’s Cancer Study Late Effects Group. Therapy based long term follow up practice statement. 2005.Google Scholar
  37. 37.
    Wong FL, Bhatia S, Landier W, et al. Cost-effectiveness of the children’s oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure. Ann Intern Med. 2014;160(10):672–83.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Yeh JM, Nohria A, Diller L. Routine echocardiography screening for asymptomatic left ventricular dysfunction in childhood cancer survivors: a model-based estimation of the clinical and economic effects. Ann Intern Med. 2014;160(10):661–71.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Kremer LC, Mulder RL, Oeffinger KC, et al. A worldwide collaboration to harmonize guidelines for the long-term follow-up of childhood and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Pediatr Blood Cancer. 2013;60(4):543–9.CrossRefPubMedGoogle Scholar
  40. 40.
    Steingart RM, Liu JE, Oeffinger KC. Cost-effectiveness of screening for asymptomatic left ventricular dysfunction in childhood cancer survivors. Ann Intern Med. 2014;160(10):731–2.CrossRefPubMedGoogle Scholar
  41. 41.
    Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):83–103.CrossRefPubMedGoogle Scholar
  42. 42.
    Dickerman JD. The late effects of childhood cancer therapy. Pediatrics. 2007;119(3):554–68.CrossRefPubMedGoogle Scholar
  43. 43.
    Nathan PC, Hayes-Lattin B, Sisler JJ, Hudson MM. Critical issues in transition and survivorship for adolescents and young adults with cancers. Cancer. 2011;117(10 Suppl):2335–41.CrossRefPubMedGoogle Scholar
  44. 44.
    Iyer NS, Mitchell HR, Zheng DJ, Ross WL, Kadan-Lottick NS. Experiences with the survivorship care plan in primary care providers of childhood cancer survivors: a mixed methods approach. Supportive Care In Cancer : Official Journal Of The Multinational Association Of Supportive Care In Cancer. 2017 May;25(5):1547–55. doi: 10.1007/s00520-016-3544-0. Epub 2017 Jan 3.
  45. 45.
    Reppucci ML, Schleien CL, Fish JD. Looking for trouble: adherence to late-effects surveillance among childhood cancer survivors. Pediatr Blood Cancer. 2017;64(2):353–7.CrossRefPubMedGoogle Scholar
  46. 46.
    Mertens AC, Cotter KL, Foster BM, et al. Improving health care for adult survivors of childhood cancer: recommendations from a delphi panel of health policy experts. Health policy (Amsterdam, Netherlands). 2004;69(2):169–78.CrossRefGoogle Scholar
  47. 47.
    Zebrack BJ, Eshelman DA, Hudson MM, et al. Health care for childhood cancer survivors: insights and perspectives from a Delphi panel of young adult survivors of childhood cancer. Cancer. 2004;100(4):843–50.CrossRefPubMedGoogle Scholar
  48. 48.
    Nathan PC, Greenberg ML, Ness KK, et al. Medical care in long-term survivors of childhood cancer: a report from the childhood cancer survivor study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(27):4401–9.CrossRefGoogle Scholar
  49. 49.
    Bhatia N, Santos M, Jones LW, et al. Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer. Circulation. 2016;133(5):537–41. doi: 10.1161/CIRCULATIONAHA.115.012519.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • Henry Chen Zheng
    • 1
  • Laura Onderko
    • 2
  • Sanjeev A. Francis
    • 3
  1. 1.Tufts University School of MedicineBostonUSA
  2. 2.Internal Medicine-Pediatrics Residency ProgramMaine Medical CenterPortlandUSA
  3. 3.Cardiovascular InstituteMaine Medical CenterPortlandUSA

Personalised recommendations